Makers of drug-device combination products are urged to anticipate postapproval changes that they may wish to make and to develop plans for the preparation of revision proposals, new FDA draft guidance says.<p>Source: <a href="http://www.fdanews.com/newsletter/article?articleId=152988&issueId=16531">http://www.fdanews.com/newsletter/article?articleId=152988&issueId=16531</a></p><p><a href="http://www.priorityprototypes.com/index.php/member/54367/">Medical Diagnostics</a> <a href="http://phil.youfailit.net/index.php/member/9008/">Diagnostics Letter</a> <a href="http://www.telemundovip.com/ee/member/227417/">Drug GMP Report</a> <a href="http://matlinglass.com/index.php/member/20968/">Capitol Hill and at the FDA</a> <a href="http://thebigbulbplant.com/member/250274/">medical equipment</a> </p>

Leave a Reply